205 related articles for article (PubMed ID: 31145831)
1. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.
Heiss JD; Lungu C; Hammoud DA; Herscovitch P; Ehrlich DJ; Argersinger DP; Sinharay S; Scott G; Wu T; Federoff HJ; Zaghloul KA; Hallett M; Lonser RR; Bankiewicz KS
Mov Disord; 2019 Jul; 34(7):1073-1078. PubMed ID: 31145831
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.
Rocco MT; Akhter AS; Ehrlich DJ; Scott GC; Lungu C; Munjal V; Aquino A; Lonser RR; Fiandaca MS; Hallett M; Heiss JD; Bankiewicz KS
Mol Ther; 2022 Dec; 30(12):3632-3638. PubMed ID: 35957524
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease.
Christine CW; Bankiewicz KS; Van Laar AD; Richardson RM; Ravina B; Kells AP; Boot B; Martin AJ; Nutt J; Thompson ME; Larson PS
Ann Neurol; 2019 May; 85(5):704-714. PubMed ID: 30802998
[TBL] [Abstract][Full Text] [Related]
4. Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
Heiss JD; Ray-Chaudhury A; Kleiner DE; Ehrlich DJ; Scott G; Edwards NA; Goldstein DS; Hammoud DA; Hadaczek P; Van Laar VS; Graff SA; Herscovitch P; Lungu C; Hallett M; Lonser RR; Zaghloul KA; Bankiewicz KS
Mov Disord; 2024 May; ():. PubMed ID: 38718138
[TBL] [Abstract][Full Text] [Related]
5. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.
Richardson RM; Kells AP; Rosenbluth KH; Salegio EA; Fiandaca MS; Larson PS; Starr PA; Martin AJ; Lonser RR; Federoff HJ; Forsayeth JR; Bankiewicz KS
Mol Ther; 2011 Jun; 19(6):1048-57. PubMed ID: 21343917
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
Marks WJ; Ostrem JL; Verhagen L; Starr PA; Larson PS; Bakay RA; Taylor R; Cahn-Weiner DA; Stoessl AJ; Olanow CW; Bartus RT
Lancet Neurol; 2008 May; 7(5):400-8. PubMed ID: 18387850
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.
Whone A; Luz M; Boca M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
Brain; 2019 Mar; 142(3):512-525. PubMed ID: 30808022
[TBL] [Abstract][Full Text] [Related]
8. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
Neurosurg Focus; 2006 May; 20(5):E1. PubMed ID: 16711657
[TBL] [Abstract][Full Text] [Related]
9. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
[TBL] [Abstract][Full Text] [Related]
10. Crossroads in GDNF therapy for Parkinson's disease.
Sherer TB; Fiske BK; Svendsen CN; Lang AE; Langston JW
Mov Disord; 2006 Feb; 21(2):136-41. PubMed ID: 16470786
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.
McGrath J; Lintz E; Hoffer BJ; Gerhardt GA; Quintero EM; Granholm AC
Cell Transplant; 2002; 11(3):215-27. PubMed ID: 12075987
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
Du Y; Zhang X; Tao Q; Chen S; Le W
Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907
[TBL] [Abstract][Full Text] [Related]
13. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
Connor B
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
[TBL] [Abstract][Full Text] [Related]
15. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.
Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B
J Neurosurg; 2005 Feb; 102(2):216-22. PubMed ID: 15739547
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors.
Ozawa K; Fan DS; Shen Y; Muramatsu S; Fujimoto K; Ikeguchi K; Ogawa M; Urabe M; Kume A; Nakano I
J Neural Transm Suppl; 2000; (58):181-91. PubMed ID: 11128607
[TBL] [Abstract][Full Text] [Related]
17. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.
Kells AP; Forsayeth J; Bankiewicz KS
Neurobiol Dis; 2012 Nov; 48(2):228-35. PubMed ID: 22019719
[TBL] [Abstract][Full Text] [Related]
18. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.
Mittermeyer G; Christine CW; Rosenbluth KH; Baker SL; Starr P; Larson P; Kaplan PL; Forsayeth J; Aminoff MJ; Bankiewicz KS
Hum Gene Ther; 2012 Apr; 23(4):377-81. PubMed ID: 22424171
[TBL] [Abstract][Full Text] [Related]
19. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
Whone AL; Boca M; Luz M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
J Parkinsons Dis; 2019; 9(2):301-313. PubMed ID: 30829619
[TBL] [Abstract][Full Text] [Related]
20. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
Gill SS; Patel NK; Hotton GR; O'Sullivan K; McCarter R; Bunnage M; Brooks DJ; Svendsen CN; Heywood P
Nat Med; 2003 May; 9(5):589-95. PubMed ID: 12669033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
